| Identification | Back Directory | [Name]
4-CHLORO-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDINE | [CAS]
479633-63-1 | [Synonyms]
Tofacitinib-9 Tofacitinib imurity Tofacitinib Impurity R Tofacitinib Impurity 53 Tofacitinib Impurity 20 4-Chloro-7-tosyl-7H-pyrro... 4-Chloro-7-tosyl-7H-pyrrolo[2 4-CHLORO-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDINE 4-Chloro-7-(p-tolylsulfonyl)pyrrolo[2,3-d]pyrimidine 4-Chloro-7-p-toluenesulphonyl-7H-pyrrolo[2,3-d]pyrimidine 4-Chloro-7-(p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 4-Chloro-7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine 4-Chloro-7-(p-toluenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine > 4-Chloro-7-[(4-methylbenzene)sulfonyl]pyrrolo[2,3-d]pyrimidine 4-CHLORO-7-[(4-METHYLPHENYL)SULFONYL]-7H-PYRROLO[2,3-D]PYRIMIDINE 4-Chloro-7-[(4-methylbenzene)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine 7H-Pyrrolo[2,3-D]pyriMidine,4-chloro-7-[(4-Methylphenyl)sulfonyl]- 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl) amino)piperidin-1-yl)-3-oxopropanenitrile | [EINECS(EC#)]
811-000-2 | [Molecular Formula]
C13H10ClN3O2S | [MDL Number]
MFCD09907939 | [MOL File]
479633-63-1.mol | [Molecular Weight]
307.76 |
| Chemical Properties | Back Directory | [Melting point ]
145.0 to 149.0 °C | [Boiling point ]
505.3±60.0 °C(Predicted) | [density ]
1.49 | [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [solubility ]
Chloroform (Slightly), DMSO (Slightly) | [form ]
powder to crystal | [pka]
1.73±0.30(Predicted) | [color ]
White to Orange to Green | [InChI]
InChI=1S/C13H10ClN3O2S/c1-9-2-4-10(5-3-9)20(18,19)17-7-6-11-12(14)15-8-16-13(11)17/h2-8H,1H3 | [InChIKey]
BTOJSYRZQZOMOK-UHFFFAOYSA-N | [SMILES]
C1=NC(Cl)=C2C=CN(S(C3=CC=C(C)C=C3)(=O)=O)C2=N1 |
| Hazard Information | Back Directory | [Uses]
4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine is a reagent in the synthesis of (+)-tofacitinib, a selective Janus kinase 3 inhibitor (JAK3) and an immunosuppressant drug. | [Pharmaceutical Applications]
4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine features a unique pyrrolo[2,3-d]pyrimidine structure, which enhances its potential as a building block in the synthesis of various biologically active molecules. Its sulfonyl group contributes to its reactivity, making it a valuable intermediate in the creation of targeted therapies, particularly in oncology and anti-inflammatory applications. | [Synthesis]
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (2kg, 12.96mol) and dichloromethane (40L) were added to the reaction flask at room temperature, stirred and dissolved. Triethylamine (3.88 kg, 38.4 mol) and 4-dimethylamino pyridine (157.6 g, 1.28 mol) were added in that order, and after stirring and dissolved, p-toluenesulfonyl chloride (2.6 kg, 13.6 mol) was added dropwise at 0 °C. The chloromethane (30 L) solution was added dropwise, and the mixture was stirred at room temperature for 30 min. After the TLC was applied, the mixture was washed with water (16L×3). 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine (3.9 kg, yield 97.7%) was obtained after drying under reduced pressure.
| [References]
[1] Patent: WO2007/117494, 2007, A1. Location in patent: Page/Page column 61-62 |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
Adamas Reagent, Ltd.
|
| Telephone: |
4006009262 13023226327 |
| Website: |
http://www.tansoole.com |
|